PHARMAC
TE PĀTAKA WHAIORANGA

Specialist Advisory Committees
Objective advice to Pharmac
www.pharmac.govt.nz

Cancer Treatments Advisory Committee Provisional recommendations 9 October 2026

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.
More information about provisional recommendations is on Pharmac's website

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Tislelizumab for the first line treatment of gastric or gastro-oesophageal junction adenocarcinoma, advanced or metastatic, HER2-negative, PD-L1 expression ≥5%, within the context of treatments for malignancy, subject to special authority criteria	Low priority
Tislelizumab for the first line treatment of oesophageal squamous cell carcinoma, advanced or metastatic, PD-L1 ≥5%, within the context of treatments for malignancy, subject to special authority criteria	Low priority
Pembrolizumab for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancers, within the context of treatments for malignancy, subject to special authority criteria	Medium priority

More information about the agenda items considered at the recent Cancer Treatments Advisory Committee meeting can be found on the Pharmac website here.

Released 16 October 2026